Skip to content

Price / book at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
5.9×-1.7×
Arrowhead Research logo
Arrowhead ResearchARWR
14.3×+11.7×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
2.5×+0.9×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
10.3×+7.2×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
10.3×+6.0×
Biogen logo
BiogenBIIB
1.4×+0.3×

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Calculated from Beam Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's price / book?
Beam Therapeutics (BEAM) reported price / book of 2.1× in Q1 2026.
How has Beam Therapeutics's price / book changed year-over-year?
Beam Therapeutics's price / book increased by 20.7% year-over-year, from 1.7× to 2.1×.
What is the long-term trend for Beam Therapeutics's price / book?
Over 5 years (2020 to 2025), Beam Therapeutics's price / book has grown at a -36.9% compound annual growth rate (CAGR), from 22.7× to 2.3×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.